Thermo Fisher Scientific Caplacizumab Humanized Recombinant Human Monoclonal Antibody

Applications

Tested Dilution

Publications

ELISA (ELISA)

Assay-dependent

-

Product Specifications

Species Reactivity

Human

Host/Isotype

Human

Expression System

CHO cells

Class

Recombinant Monoclonal

Type

Antibody

Immunogen

Human VWF A1 domain

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

1.6 mg/mL

Purification

Metal-chelate chromatography

Storage buffer

20mM citric acid with 6.2% sucrose, 0.01% Tween 80

Contains

no preservative

Storage conditions

-20° C, Avoid Freeze/Thaw Cycles

Shipping conditions

Ambient (domestic); Wet ice (international)

RRID

AB_2911097

Product Specific Information

Endotoxin level < 0.01EU/µg by LAL method

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 °C for one week. Store at -20 to -80 °C for twelve months from the date of receipt.

Target Information

Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker. Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019, 6and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.